Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
NEW HAVEN, Conn., April 11, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced that Jennifer Good, President and Chief Executive Officer, Lisa Delfini, Chief Financial Officer, and David Clark, MD, Chief Medical Officer, will be participating in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, at 11:00 a.m. ET. Ms. Good and Ms. Delfini will also participate in investor meetings with attendees.
- Fireside chat will be held on Monday, April 17, 2023, at 11:00 a.m.
- Ms. Good and Ms. Delfini will also participate in investor meetings with attendees.
- A live webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
- An archived replay of the webcast will also be available for 30 days on the Company's website following the event.